TORgeting oncogene addiction for cancer therapy. Academic Article uri icon

Overview

abstract

  • The PI3K-Akt-mTOR growth-regulating pathway is conserved from mammals to flies and hyperactivated in many cancers. Accordingly, rapamycin analogs, which are inhibitors of mTOR-Raptor signaling, have recently garnered much interest as potential therapeutic agents against cancer. However, due to the heterogeneity of tumors, prior knowledge of the genetic and biochemical background of cancer cells will be required for effective targeted therapy. Thus, the identification of biological markers against activated oncogenic pathways is needed. In the January issue of Nature Medicine, Thomas et al. identify the loss of VHL tumor suppressor gene as a potential determining factor in tumor sensitivity to rapamycin.

publication date

  • February 1, 2006

Research

keywords

  • Neoplasms
  • Oncogenes
  • Protein Kinases
  • Sirolimus
  • Von Hippel-Lindau Tumor Suppressor Protein

Identity

Scopus Document Identifier

  • 32044445067

Digital Object Identifier (DOI)

  • 10.1016/j.ccr.2006.01.021

PubMed ID

  • 16473275

Additional Document Info

volume

  • 9

issue

  • 2